Interestingly, it has even been reported that some patients with somatic NRAS (especially the NRASG12S) (40) and KRAS (especially the KRASG12V) (41) mutations, may have an indolent course or even spontaneously regress their MPN. Here, KRAS is linked to myeloproliferative disorder.